BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28668864)

  • 1. Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
    Okano N; Kasuga A; Kawai K; Kobayashi T; Naruge D; Nagashima F; Furuse J
    Anticancer Res; 2017 Jul; 37(7):3711-3715. PubMed ID: 28668864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
    Okano N; Furuse J; Ueno M; Morizane C; Yamanaka T; Ojima H; Ozaka M; Sasaki M; Takahara N; Nakai Y; Kobayashi S; Morimoto M; Hosoi H; Maeno S; Nagashima F; Ikeda M; Okusaka T
    Oncologist; 2021 Feb; 26(2):97-e201. PubMed ID: 33010112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of axitinib in advanced neuroendocrine tumors.
    Strosberg JR; Cives M; Hwang J; Weber T; Nickerson M; Atreya CE; Venook A; Kelley RK; Valone T; Morse B; Coppola D; Bergsland EK
    Endocr Relat Cancer; 2016 May; 23(5):411-8. PubMed ID: 27080472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
    Spano JP; Moore MJ; Pithavala YK; Ricart AD; Kim S; Rixe O
    Invest New Drugs; 2012 Aug; 30(4):1531-9. PubMed ID: 21670972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
    Cohen EE; Tortorici M; Kim S; Ingrosso A; Pithavala YK; Bycott P
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1261-70. PubMed ID: 25315258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
    Spano JP; Chodkiewicz C; Maurel J; Wong R; Wasan H; Barone C; Létourneau R; Bajetta E; Pithavala Y; Bycott P; Trask P; Liau K; Ricart AD; Kim S; Rixe O
    Lancet; 2008 Jun; 371(9630):2101-8. PubMed ID: 18514303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
    Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
    Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
    Bondarenko IM; Ingrosso A; Bycott P; Kim S; Cebotaru CL
    BMC Cancer; 2015 May; 15():339. PubMed ID: 25929582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study.
    Jo JH; Kang H; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):62-66. PubMed ID: 30612929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
    Kindler HL; Ioka T; Richel DJ; Bennouna J; Létourneau R; Okusaka T; Funakoshi A; Furuse J; Park YS; Ohkawa S; Springett GM; Wasan HS; Trask PC; Bycott P; Ricart AD; Kim S; Van Cutsem E
    Lancet Oncol; 2011 Mar; 12(3):256-62. PubMed ID: 21306953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
    Ioka T; Okusaka T; Ohkawa S; Boku N; Sawaki A; Fujii Y; Kamei Y; Takahashi S; Namazu K; Umeyama Y; Bycott P; Furuse J
    Jpn J Clin Oncol; 2015 May; 45(5):439-48. PubMed ID: 25647781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
    Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
    Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI
    Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
    Locati LD; Licitra L; Agate L; Ou SH; Boucher A; Jarzab B; Qin S; Kane MA; Wirth LJ; Chen C; Kim S; Ingrosso A; Pithavala YK; Bycott P; Cohen EE
    Cancer; 2014 Sep; 120(17):2694-703. PubMed ID: 24844950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
    Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
    Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.